Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry

S. D. Ferrara, L. Tedeschi, G. Frison, F. Castagna, L. Gallimberti, R. Giorgetti, G. L. Gessa, P. Palatini

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

A gas chromatographic-mass spectrometric (GC-MS) method for the determination of therapeutic levels of gamma-hydroxybutyric acid (GHB) in plasma and urine samples is described. GHB is converted to its lactonic form gamma-butyrolactone (GBL) which is extracted from biological fluids after the addition of the internal standard delta-valerolactone. Final GC-MS analysis is obtained under electron impact selected ion monitoring (SIM) conditions. Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively. The assay is linear over a plasma GHB range of 2-200 μg ml-1 (r = 0.999) and a urine GHB range of 2-150 μg ml-1 (r = 0.998). Intra- and inter-assay relative standard deviations (n = 5) determined at 10 and 100 μg ml-1 are below 5%. The method is simple, specific and accurate, and may be applied for analytical purposes related to pharmacokinetic studies and therapeutic drug monitoring.

Original languageEnglish
Pages (from-to)483-487
Number of pages5
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume11
Issue number6
DOIs
Publication statusPublished - 1993

Fingerprint

Plasma Gases
Gas chromatography
Gas Chromatography-Mass Spectrometry
Mass spectrometry
Urine
Plasmas
Monitoring
Assays
Gases
4-Butyrolactone
Therapeutics
Pharmacokinetics
Drug Monitoring
Condition monitoring
4-hydroxybutyric acid
Electrons
Ions
Recovery
Fluids
Pharmaceutical Preparations

Keywords

  • Gamma-hydroxybutyric acid
  • GC-MS.
  • therapeutic drug monitoring

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science

Cite this

Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. / Ferrara, S. D.; Tedeschi, L.; Frison, G.; Castagna, F.; Gallimberti, L.; Giorgetti, R.; Gessa, G. L.; Palatini, P.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 11, No. 6, 1993, p. 483-487.

Research output: Contribution to journalArticle

Ferrara, SD, Tedeschi, L, Frison, G, Castagna, F, Gallimberti, L, Giorgetti, R, Gessa, GL & Palatini, P 1993, 'Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry', Journal of Pharmaceutical and Biomedical Analysis, vol. 11, no. 6, pp. 483-487. https://doi.org/10.1016/0731-7085(93)80161-S
Ferrara, S. D. ; Tedeschi, L. ; Frison, G. ; Castagna, F. ; Gallimberti, L. ; Giorgetti, R. ; Gessa, G. L. ; Palatini, P. / Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. In: Journal of Pharmaceutical and Biomedical Analysis. 1993 ; Vol. 11, No. 6. pp. 483-487.
@article{753d0e165c754152b21acfa8b252b960,
title = "Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry",
abstract = "A gas chromatographic-mass spectrometric (GC-MS) method for the determination of therapeutic levels of gamma-hydroxybutyric acid (GHB) in plasma and urine samples is described. GHB is converted to its lactonic form gamma-butyrolactone (GBL) which is extracted from biological fluids after the addition of the internal standard delta-valerolactone. Final GC-MS analysis is obtained under electron impact selected ion monitoring (SIM) conditions. Mean relative recoveries of GHB from plasma and urine are 75.5{\%} (RSD{\%} = 2.2) and 76.4{\%} (RSD{\%} = 2.4), respectively. The assay is linear over a plasma GHB range of 2-200 μg ml-1 (r = 0.999) and a urine GHB range of 2-150 μg ml-1 (r = 0.998). Intra- and inter-assay relative standard deviations (n = 5) determined at 10 and 100 μg ml-1 are below 5{\%}. The method is simple, specific and accurate, and may be applied for analytical purposes related to pharmacokinetic studies and therapeutic drug monitoring.",
keywords = "Gamma-hydroxybutyric acid, GC-MS., therapeutic drug monitoring",
author = "Ferrara, {S. D.} and L. Tedeschi and G. Frison and F. Castagna and L. Gallimberti and R. Giorgetti and Gessa, {G. L.} and P. Palatini",
year = "1993",
doi = "10.1016/0731-7085(93)80161-S",
language = "English",
volume = "11",
pages = "483--487",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry

AU - Ferrara, S. D.

AU - Tedeschi, L.

AU - Frison, G.

AU - Castagna, F.

AU - Gallimberti, L.

AU - Giorgetti, R.

AU - Gessa, G. L.

AU - Palatini, P.

PY - 1993

Y1 - 1993

N2 - A gas chromatographic-mass spectrometric (GC-MS) method for the determination of therapeutic levels of gamma-hydroxybutyric acid (GHB) in plasma and urine samples is described. GHB is converted to its lactonic form gamma-butyrolactone (GBL) which is extracted from biological fluids after the addition of the internal standard delta-valerolactone. Final GC-MS analysis is obtained under electron impact selected ion monitoring (SIM) conditions. Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively. The assay is linear over a plasma GHB range of 2-200 μg ml-1 (r = 0.999) and a urine GHB range of 2-150 μg ml-1 (r = 0.998). Intra- and inter-assay relative standard deviations (n = 5) determined at 10 and 100 μg ml-1 are below 5%. The method is simple, specific and accurate, and may be applied for analytical purposes related to pharmacokinetic studies and therapeutic drug monitoring.

AB - A gas chromatographic-mass spectrometric (GC-MS) method for the determination of therapeutic levels of gamma-hydroxybutyric acid (GHB) in plasma and urine samples is described. GHB is converted to its lactonic form gamma-butyrolactone (GBL) which is extracted from biological fluids after the addition of the internal standard delta-valerolactone. Final GC-MS analysis is obtained under electron impact selected ion monitoring (SIM) conditions. Mean relative recoveries of GHB from plasma and urine are 75.5% (RSD% = 2.2) and 76.4% (RSD% = 2.4), respectively. The assay is linear over a plasma GHB range of 2-200 μg ml-1 (r = 0.999) and a urine GHB range of 2-150 μg ml-1 (r = 0.998). Intra- and inter-assay relative standard deviations (n = 5) determined at 10 and 100 μg ml-1 are below 5%. The method is simple, specific and accurate, and may be applied for analytical purposes related to pharmacokinetic studies and therapeutic drug monitoring.

KW - Gamma-hydroxybutyric acid

KW - GC-MS.

KW - therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=0027287692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027287692&partnerID=8YFLogxK

U2 - 10.1016/0731-7085(93)80161-S

DO - 10.1016/0731-7085(93)80161-S

M3 - Article

C2 - 8399519

AN - SCOPUS:0027287692

VL - 11

SP - 483

EP - 487

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 6

ER -